International Journal of Psychiatry in Medicine最新文献

筛选
英文 中文
Elder abuse and neglect, novel factors affecting depression risk, SARS-CoV-2 Omicron-induced anxiety, and provider flourishing in pediatric palliative care. 老年人虐待和忽视、影响抑郁风险的新因素、SARS-CoV-2 Omicron 引起的焦虑以及儿科姑息治疗中提供者的蓬勃发展。
IF 1.1 4区 医学
International Journal of Psychiatry in Medicine Pub Date : 2024-09-07 DOI: 10.1177/00912174241284120
Harold G Koenig
{"title":"Elder abuse and neglect, novel factors affecting depression risk, SARS-CoV-2 Omicron-induced anxiety, and provider flourishing in pediatric palliative care.","authors":"Harold G Koenig","doi":"10.1177/00912174241284120","DOIUrl":"https://doi.org/10.1177/00912174241284120","url":null,"abstract":"","PeriodicalId":50294,"journal":{"name":"International Journal of Psychiatry in Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-09-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142146739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Red kratom and red corvette: A case of mania induced by kratom withdrawal. 红色桔梗和红色雪佛兰一例由克来托戒断诱发的躁狂症。
IF 1.1 4区 医学
International Journal of Psychiatry in Medicine Pub Date : 2024-09-06 DOI: 10.1177/00912174241281980
Mohammmad Abidali, Guitelle St Victor, Shady Mashaly, Pranab Dahal
{"title":"Red kratom and red corvette: A case of mania induced by kratom withdrawal.","authors":"Mohammmad Abidali, Guitelle St Victor, Shady Mashaly, Pranab Dahal","doi":"10.1177/00912174241281980","DOIUrl":"https://doi.org/10.1177/00912174241281980","url":null,"abstract":"<p><p><b>Background:</b> Kratom, derived from the <i>Mitragyna speciose, a</i>  plant native to Southeast Asia, is a substance that is gaining popularity in the United States as a self-medication tool for opiate withdrawal and pain management. Its active compounds, mitragynine, and 7-hydroxymitragynine, interact with various receptors in the body, resulting in a spectrum of clinical effects.<b>Case:</b> A 56-year-old male with a history of depression and cannabis use disorder arrived at the Emergency Department in a state of severe agitation with erratic behavior and aggression. Further evaluation revealed a recent abrupt discontinuation of Kratom use. A psychiatric consultation was requested and done by our consultation-liaison team, diagnosing Kratom withdrawal as the <b>most likely</b> cause of his acute mania. Neuropsychiatric symptoms arising from Kratom toxicity is a well-documented phenomenon; however, to our knowledge, this <b>may be</b> the first documented case of acute mania induced by Kratom withdrawal.</p>","PeriodicalId":50294,"journal":{"name":"International Journal of Psychiatry in Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-09-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142141581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Psychotropic medication and hepatobiliary health: Ultrasound observations on patients with schizophrenia. 精神药物与肝胆健康:对精神分裂症患者的超声波观察。
IF 1.1 4区 医学
International Journal of Psychiatry in Medicine Pub Date : 2024-09-05 DOI: 10.1177/00912174241280510
Linlin Yue, Linlin Sun, Nan Li
{"title":"Psychotropic medication and hepatobiliary health: Ultrasound observations on patients with schizophrenia.","authors":"Linlin Yue, Linlin Sun, Nan Li","doi":"10.1177/00912174241280510","DOIUrl":"https://doi.org/10.1177/00912174241280510","url":null,"abstract":"<p><strong>Objective: </strong>This study sought to examine the association between antipsychotic drug use and hepatobiliary health based on serum markers and ultrasound observations on a sample of patients with schizophrenia compared to age and gender matched healthy controls.</p><p><strong>Methods: </strong>The 120 patients with schizophrenia and 60 control subjects had their blood drawn to measure liver function tests and underwent hepatobiliary ultrasonography to determine hepatobiliary lesions. Liver function tests included total cholesterol (TC), triglycerides (TG), alanine aminotransferase (ALT), and aspartate aminotransferase (AST). Standardized cross-sectional images of the liver and kidneys were obtained from patients and controls, and analyses were stratified by length of taking psychotropic medication among those with schizophrenia. Liver echo attenuation coefficients, liver-kidney ratios, and liver fat content were determined.</p><p><strong>Results: </strong>Psychotropic drug use was associated with greater liver burden and liver lesions in patients with schizophrenia compared to controls. The levels of TC, TG, ALT and AST in patients with schizophrenia were also all significantly higher among patients with schizophrenia. Long-term psychotropic medication was associated with increased levels of fatty liver in patients compared with controls. Levels of TC, TG, ALT and AST were all significantly higher in the long-term psychotropic medication use group than in the short-term group. Liver echo attenuation coefficient, liver-kidney ratio, and liver fat content were also higher in the long-term medication use group compared to the short-term group.</p><p><strong>Conclusion: </strong>Antipsychotic drug use, particularly long-term use, is associated with increased liver burden in patients with schizophrenia, impaired lipid metabolism, increased liver lesions and fat content.</p>","PeriodicalId":50294,"journal":{"name":"International Journal of Psychiatry in Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-09-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142134322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The efficacy and safety of adding celecoxib to escitalopram for improving symptoms of major depressive disorder. 在艾司西酞普兰中添加塞来昔布改善重度抑郁症状的有效性和安全性。
IF 1.1 4区 医学
International Journal of Psychiatry in Medicine Pub Date : 2024-09-01 Epub Date: 2023-11-21 DOI: 10.1177/00912174231210567
Mohammad Nadi Sakhvidi, Zanireh Salami, Maryam Mosadegh, Reza Bidaki, Hossien Fallahzadeh, Razie Salehabadi, Malihe Arjmandi
{"title":"The efficacy and safety of adding celecoxib to escitalopram for improving symptoms of major depressive disorder.","authors":"Mohammad Nadi Sakhvidi, Zanireh Salami, Maryam Mosadegh, Reza Bidaki, Hossien Fallahzadeh, Razie Salehabadi, Malihe Arjmandi","doi":"10.1177/00912174231210567","DOIUrl":"10.1177/00912174231210567","url":null,"abstract":"<p><strong>Objective: </strong>There is growing evidence that adding non-steroidal anti-inflammatory drugs to some psychopharmacological treatments may help to improve symptoms in patients suffering from major depressive disorder. The present study examined the therapeutic efficacy of adding celecoxib to escitalopram and the safety of doing so.</p><p><strong>Method: </strong>In this double-blind randomized controlled trial, 60 patients with major depressive disorder were randomly assigned to either treatment with escitalopram plus celecoxib (intervention group) or escitalopram and placebo. All patients were evaluated blind to treatment group with the Hamilton Depression Rating Scale (HDRS) before the intervention as well at 4 and 8 weeks after initiating treatment. Chi-square and paired t-test were used to examine between-group differences at those assessment times.</p><p><strong>Results: </strong>There was no significant difference in depressive symptoms between intervention and placebo groups at baseline. However, at 4 and 8 weeks after the beginning of treatment, there were significant between-group differences in HDRS scores, favoring the intervention group. No between-group differences were found in treatment-related side effects.</p><p><strong>Conclusions: </strong>Adding celecoxib to escitalopram may improve symptoms of depression in patients with major depressive disorder without increasing the risk of drug-related side effects.</p>","PeriodicalId":50294,"journal":{"name":"International Journal of Psychiatry in Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138812581","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Comparison of ketamine with buprenorphine as adjunctive therapy in the treatment of comorbid major depressive disorder and opium use disorders: A randomized controlled trial. 氯胺酮与丁丙诺啡作为辅助疗法治疗合并重度抑郁障碍和鸦片使用障碍的比较:随机对照试验。
IF 1.1 4区 医学
International Journal of Psychiatry in Medicine Pub Date : 2024-09-01 Epub Date: 2023-12-23 DOI: 10.1177/00912174231225087
Jamshid Ahmadi, Arash Mansoori, Seyed Hamdollah Mosavat, Amir Bazrafshan
{"title":"Comparison of ketamine with buprenorphine as adjunctive therapy in the treatment of comorbid major depressive disorder and opium use disorders: A randomized controlled trial.","authors":"Jamshid Ahmadi, Arash Mansoori, Seyed Hamdollah Mosavat, Amir Bazrafshan","doi":"10.1177/00912174231225087","DOIUrl":"10.1177/00912174231225087","url":null,"abstract":"<p><strong>Background: </strong>Comorbid major depressive disorder (MDD) and opium use disorder (OUD) are known to increase the risk of suicide. The purpose of this study was to compare the efficacy and safety of adjunctive therapy with either ketamine or buprenorphine in patients with comorbid MDD and OUD.</p><p><strong>Methods: </strong>This was a randomized double-blind controlled trial in adults admitted to a hospital in Iran. Sixty-six participants were enrolled and received either ketamine or buprenorphine, along with current antidepressant therapy. The primary outcome was change in depressive symptoms assessed using the Beck Depression Inventory (BDI) after 2 hours, 24 hours, and 7 days following initiation of treatment. Secondary outcomes included changes in suicidal ideation, evaluated by the Beck Scale for Suicidal Ideation (BSSI).</p><p><strong>Results: </strong>Both groups experienced a significant decrease in the severity of depression following the interventions (<i>p</i> < .05). However, there was no significant difference in the between-group comparison (<i>p</i> > .05). Both groups also exhibited a significant reduction in suicidal ideation compared to before the study, with the decrease in severity being over 85% in both groups (<i>p</i> < .05).</p><p><strong>Conclusion: </strong>Both ketamine and buprenorphine appear to be equally effective in reducing symptoms of depression and suicidal ideation among individuals with MDD and OUD.</p>","PeriodicalId":50294,"journal":{"name":"International Journal of Psychiatry in Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138886503","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A randomized controlled trial of repetitive transcranial magnetic stimulation plus donepezil vs donepezil alone for mild to moderate cognitive impairment due to small vessel cerebrovascular disease. 重复经颅磁刺激加多奈哌齐与单用多奈哌齐治疗小血管脑血管疾病引起的轻中度认知障碍的随机对照试验。
IF 1.1 4区 医学
International Journal of Psychiatry in Medicine Pub Date : 2024-09-01 Epub Date: 2024-01-17 DOI: 10.1177/00912174241227513
Bijiang Shou, Xuan Chen, Yuli Hou
{"title":"A randomized controlled trial of repetitive transcranial magnetic stimulation plus donepezil vs donepezil alone for mild to moderate cognitive impairment due to small vessel cerebrovascular disease.","authors":"Bijiang Shou, Xuan Chen, Yuli Hou","doi":"10.1177/00912174241227513","DOIUrl":"10.1177/00912174241227513","url":null,"abstract":"<p><strong>Objectives: </strong>Small vessel cerebrovascular disease (SVCVD) accounts for 35% to 67% of vascular dementias, and may be overlooked by healthcare providers due to its insidious onset. SVCVD involves chronic cerebral ischemia and hypoperfusion, endothelial dysfunction, blood-brain barrier disruption, and interstitial fluid reflux. The purpose of this study was to investigate the clinical efficacy of repetitive transcranial magnetic stimulation (rTMS) combined with donepezil hydrochloride compared to donepezil alone in the treatment of mild-to-moderate cognitive impairment in patients with SVCVD.</p><p><strong>Material and methods: </strong>A cohort of 115 individuals with mild-to-moderate cognitive impairment due to SVCVD was purposefully selected and randomized into two groups: a test group and a control group. The test group received a combination of repetitive transcranial magnetic stimulation (rTMS) and oral donepezil hydrochloride (10 mg/day), while the control group received oral donepezil alone (10 mg/day). The Mini-Mental State Examination (MMSE) and Montreal Cognitive Assessment (MoCA) scores were evaluated in both groups prior to and following the interventions.</p><p><strong>Results: </strong>Following 6 weeks of treatment, both groups demonstrated enhancement in cognitive function. However, a statistically significant difference was observed between the test group and the control group (<i>p</i> < .05 on both the MMSE and the MOCA), favoring the test group.</p><p><strong>Conclusions: </strong>Compared to donepezil alone, the combination of repetitive transcranial magnetic stimulation (rTMS) and donepezil has a significantly greater effect on enhancing cognitive function among individuals experiencing mild-to-moderate cognitive impairment resulting from SVCVD.</p>","PeriodicalId":50294,"journal":{"name":"International Journal of Psychiatry in Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139486584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Agomelatine efficacy in treatment resistant obsessive-compulsive disorder: A randomized controlled trial. 阿戈美拉汀对抗药性强迫症的疗效:随机双盲临床试验
IF 1.1 4区 医学
International Journal of Psychiatry in Medicine Pub Date : 2024-09-01 Epub Date: 2023-12-29 DOI: 10.1177/00912174231225763
Azadeh Nejati, Amir Bazrafshan, Seyed Hamdollah Mosavat
{"title":"Agomelatine efficacy in treatment resistant obsessive-compulsive disorder: A randomized controlled trial.","authors":"Azadeh Nejati, Amir Bazrafshan, Seyed Hamdollah Mosavat","doi":"10.1177/00912174231225763","DOIUrl":"10.1177/00912174231225763","url":null,"abstract":"<p><strong>Background: </strong>Obsessive-compulsive disorder (OCD) is a prevalent and burdensome mental health condition, often resistant to conventional treatments. Agomelatine (Valdoxan), a compound acting on serotonin and melatonin systems, has shown promise in treating those with treatment-resistant OCD based on anecdotal reports and case studies.</p><p><strong>Methods: </strong>A randomized, double-blind controlled trial was conducted with 60 patients diagnosed with treatment-resistant OCD. Participants were randomized into an intervention group (receiving agomelatine 50 mg/day) and a control group (receiving placebo). OCD symptoms were assessed using the Yale-Brown Obsessive-Compulsive Scale (Y-BOCS) over a 12-week period.</p><p><strong>Results: </strong>There were no significant differences in age, gender, or baseline Y-BOCS scores between intervention and control groups. Agomelatine did not demonstrate a significant improvement in OCD symptoms compared to placebo. Adverse events were comparable between groups, and liver enzyme levels remained within the normal range.</p><p><strong>Conclusion: </strong>This study, while not confirming superior efficacy compared to placebo, underscores the need for continued investigation into agomelatine's potential for treating specific subgroups of OCD patients, underscoring the need for more comprehensive and well-controlled trials in the future.</p>","PeriodicalId":50294,"journal":{"name":"International Journal of Psychiatry in Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139075751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Impact of social support and religiosity/spirituality on recovery from acute cardiac events and heart surgery in Switzerland. 在一项瑞士研究中,社会支持和宗教信仰/灵性对急性心脏事件和心脏手术后恢复的影响。
IF 1.1 4区 医学
International Journal of Psychiatry in Medicine Pub Date : 2024-09-01 Epub Date: 2023-12-29 DOI: 10.1177/00912174231225801
Micha Eglin, Jean-Paul Schmid, Joram Ronel, Ramin Khatami, Christoph Leiggener, Harold G Koenig, René Hefti
{"title":"Impact of social support and religiosity/spirituality on recovery from acute cardiac events and heart surgery in Switzerland.","authors":"Micha Eglin, Jean-Paul Schmid, Joram Ronel, Ramin Khatami, Christoph Leiggener, Harold G Koenig, René Hefti","doi":"10.1177/00912174231225801","DOIUrl":"10.1177/00912174231225801","url":null,"abstract":"<p><strong>Objective: </strong>The aim of this study was to evaluate the impact of social support and religiosity/spirituality (R/S) on the recovery from an acute cardiac event or cardiac surgery during cardiac rehabilitation (CR).</p><p><strong>Methods: </strong>In this prospective study, a convenience sample of 159 patients participating in a CR program were enrolled. Religiosity/spirituality, social support, anxiety, depression, health related quality of life (QoL), and exercise capacity (6-min walk test, cycle ergometer test) were assessed.</p><p><strong>Results: </strong>Social support was significantly associated with less anxiety (<i>p</i> < .01), less depression (<i>p</i> < .01), and better QoL (<i>p</i> < .05) on admission. After adjustment for age, gender, education level, and morbidity, social support remained significantly associated with less depression (<i>p</i> < .001). Religiosity/spirituality was significantly associated with less depression (<i>p</i> < .05), better QoL (<i>p</i> < .05), and better exercise capacity (<i>p</i> < .05) at admission. After adjustment for covariates, however, significance was lost. There were no significant impact of either social support or R/S on the course of CR measured by change in QoL or exercise capacity.</p><p><strong>Conclusion: </strong>Social support may be a protective factor against depression in the recovery from cardiac events or surgery. Neither social support nor R/S had a significant impact on the course of the 3-week CR program.</p>","PeriodicalId":50294,"journal":{"name":"International Journal of Psychiatry in Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139059033","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The clozapine conundrum: Navigating neutropenia and the pursuit of effective care in treatment-resistant schizophrenia. 氯氮平难题:在难治性精神分裂症中导航中性粒细胞减少症和追求有效护理。
IF 1.1 4区 医学
International Journal of Psychiatry in Medicine Pub Date : 2024-09-01 Epub Date: 2023-11-16 DOI: 10.1177/00912174231214647
Anindya Kar, Thomas Nutting, Mohammad Ikram, Charles Sullivan
{"title":"The clozapine conundrum: Navigating neutropenia and the pursuit of effective care in treatment-resistant schizophrenia.","authors":"Anindya Kar, Thomas Nutting, Mohammad Ikram, Charles Sullivan","doi":"10.1177/00912174231214647","DOIUrl":"10.1177/00912174231214647","url":null,"abstract":"<p><p><b>Background:</b> This case explores the challenges encountered in managing treatment-resistant paranoid schizophrenia, focusing on the limitations of using clozapine due to the risk of neutropenia. The United Kingdom Clozapine Patient Monitoring Service (UK CPMS) and its eligibility criteria are discussed, highlighting the potential benefits of expanding access to clozapine for patients who could potentially benefit from this medication. The integration of clozapine genetic testing as a personalized approach is explored, emphasizing the importance of identifying patients with a favorable genetic profile for clozapine response.<b>Methods:</b> Case report.<b>Results:</b> The case presentation of Mr. X exemplifies the difficulties faced in managing treatment-resistant schizophrenia when access to clozapine is restricted, leading to persistent negative symptoms.<b>Conclusion:</b> The article underscores the importance of innovative solutions and personalized care to enhance the treatment outcomes for patients with treatment-resistant paranoid schizophrenia. It acknowledges that certain restrictions of clozapine use may limit the effective management of patients with this condition.</p>","PeriodicalId":50294,"journal":{"name":"International Journal of Psychiatry in Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136400117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Functional neurological disorder in Saudi Arabia: A retrospective study. 沙特阿拉伯的功能性神经障碍:一项回顾性研究。
IF 1.1 4区 医学
International Journal of Psychiatry in Medicine Pub Date : 2024-09-01 Epub Date: 2023-11-10 DOI: 10.1177/00912174231215908
Haythum O Tayeb
{"title":"Functional neurological disorder in Saudi Arabia: A retrospective study.","authors":"Haythum O Tayeb","doi":"10.1177/00912174231215908","DOIUrl":"10.1177/00912174231215908","url":null,"abstract":"<p><strong>Objectives: </strong>To describe the clinical profile of a sample of Saudi patients with Functional Neurological Disorder (FND).</p><p><strong>Method: </strong>A retrospective chart review of FND patients seen from 2021-2023 at a neuropsychiatry clinic at an academic tertiary care center in Jeddah, Saudi Arabia.</p><p><strong>Results: </strong>Out of 473 patients seen in the clinic during the review period, 52 (11%) had FND. Mean age was 34 years (standard deviation = 10.7), and 77% were female. Family dispute (39%) was the most reported risk factor, followed by sexual abuse (15%). The most common FND symptoms were nonepileptic seizures (61.5%) and abnormal movements (30.8%). Pain was reported by 57.7% and cognitive symptoms by 36.5%. FND symptoms were frequently attributed to supernatural causes (67.3%). During the last follow-up visit, 53.9% of patients reported FND symptom improvement, whereas 21.2% reported no change, 10.2% reported worsening, and 15% were lost to follow-up. The proportion of patients without symptom improvement was higher among patients with cognitive symptoms (45.5% vs 18% respectively, X<sub>2</sub> = 10.08, df = 3, <i>p</i> = .018). The mean number of visits was highest in patients reporting worsening and the lowest was among patients reporting no change (F = 4.21, <i>p</i> = .017).</p><p><strong>Conclusion: </strong>The role of family disputes in FND in the Middle East, the role of supernatural concepts in how FND is perceived, and the relatively high rate of subjective improvement within this sample of Saudi FND patients merit further exploration. Cognitive symptoms may be another prognostic indicator. Prospective multicenter studies of those with FND using standardized assessment measures are needed.</p>","PeriodicalId":50294,"journal":{"name":"International Journal of Psychiatry in Medicine","volume":null,"pages":null},"PeriodicalIF":1.1,"publicationDate":"2024-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"72016014","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信